Durable PSA Control After Testosterone Recovery in High‑Risk Biochemical Recurrent Prostate Cancer

A recent post hoc analysis of the phase 3 EMBARK trial in high‑risk biochemical recurrent prostate cancer has generated considerable interest because it suggests that durable, long‑term PSA control can occur even after testosterone has fully recovered to eugonadal levels, challenging the conventional assumption that hormonal suppression must be continuous to maintain remission. The analysis […]

Subgroup Analysis of The ARASENS Trial

The ARASENS trial, a large phase 3 study, investigated the impact of adding darolutamide, a novel androgen receptor inhibitor, to the standard treatment of androgen-deprivation therapy (ADT) and docetaxel chemotherapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). A recent subgroup analysis focused on whether the benefits of this combination extend across age groups. In […]

PSA Level at 6 Months as a Predictor of Long-Term Outcomes: Real 10-Year Overall Survival Data from the CHAARTED Trial

A New Insight From the ARANOTE Trial for mHSPC

Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins